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an Measuring
he Ankle-Brachial
ndex Improve Public Health?*
illiam R. Hiatt, MD, FAHA
enver, Colorado
eripheral artery disease (PAD) is a common manifestation of
ystemic atherosclerosis, with a prevalence ranging from 4% in
he healthy U.S. adult population over the age of 40 years, to
9% in patients screened in primary care offices, with diabetes,
igarette smoking, and age as risk factors (1,2). Peripheral
rtery disease is highly associated with the risk of cardiovascular
schemic events and excess total mortality. Identification and
uantification of this systemic risk have been established from
umerous population-based and observational case-control
tudies, which have profound public health implications.
See page 1736
Although the PAD risk of systemic cardiovascular events
s driven primarily by concomitant coronary and cerebro-
ascular disease, there are several modifiers of the risk,
ncluding the symptomatic severity of the disease and the
umber of vascular territories affected. Patients with clau-
ication (symptoms during walking exercise) have far lower
ortality event rates (1% to 2%/year) than do patients with
ritical limb ischemia (defined as ischemic symptoms at rest,
lceration, or gangrene), with an annual mortality risk of up
o 12%/year (3,4). In patients with PAD who have no other
linical evidence of coronary or cerebral disease, the annual
isk of myocardial infarction, stroke, and vascular death is
pproximately 3%/year. However, adding clinical coronary
isease increases the event rate to approximately 6%/year,
nd in patients with all three territories affected, the event
ate is as high as 9%/year (5). Additional factors that
ncrementally define the cardiovascular risk in PAD include
he functional status of the patient (6) and the level of
ystemic inflammation (7).
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Medicine, University of Colorado Denver School ofA
edicine, Denver, Colorado. Steven E. Nissen, MD, served as Guest Editor for this
rticle.Identification of PAD is often based on a simple, risk-free,
nd cost-effective hemodynamic test, the ankle-brachial index
ABI). Typically, a Doppler ultrasonography instrument is
sed to identify the arterial pulse, and systolic pressures are
easured in both arms and at the dorsalis pedis and posterior
ibial arteries at the ankles. These measurements are made with
he patient supine and usually can be obtained in 15 minutes
8). Each of the ankle pressures is normalized to the single
ighest arm pressure, and values 0.90 are considered diag-
ostic of the disease. In addition to using a single cut-point for
he diagnosis of PAD, the hemodynamic disease severity across
he range of ABI values 1.00 is also highly associated with
isk (9). More recently, the independent contribution of the
BI to assessment of cardiovascular risk has been defined by an
nternational ABI meta-analysis that included more than
80,000 person-years of follow-up in 24,955 men and 23,339
omen (10). After adjustment for the Framingham risk score,
he ABI provided significant improvement in predicting car-
iovascular risk independent of established risk factors in a
road population. In fact, the ABI resulted in reclassification of
he Framingham risk estimate in approximately 20% of men
nd one-third of women.
Based on this background, in this issue of the JournalCriqui
t al. (11) evaluated changes in the ABI over time as a predictor
f cardiovascular morbidity and mortality. They hypothesized
hat patients with a more rapid decline in the ABI value would
ave a higher risk than patients with a stable ABI. Patients
ere identified from vascular laboratories, and baseline ABI
alues were obtained from chart abstraction. A second visit to
he vascular laboratory (on average, 5 years from baseline) was
sed to determine the change in the ankle-brachial index over
ime. At the second visit, the authors observed an independent,
nverse association between ABI and all-cause and cardiovas-
ular mortality at 3- and 6-year follow-up, as previously
escribed (9). Patients were further evaluated based on the
hange score of the ABI divided into tertiles of changes0.15,
hanges0.15, and decreases0.15. Patients with a decrease
n the ABI had a significant increase in all-cause and cardio-
ascular mortality compared with patients with stable measure-
ents. These associations were particularly strong at 3 years
nd weakened at 6 years of follow-up. Thus, both the severity
f the hemodynamic disease process and the rate of progression
f leg arterial disease were associated with increased risk of
ardiovascular and all-cause mortality. Similar findings have
lso been reported in another cohort study in which patients
ere evaluated with resting and post-exercise ABI over time
12). The study by Criqui et al. (11) further anchors the clinical
vidence that associates the severity of lower extremity arterial
isease with risk of major systemic, and often life-threatening,
ardiovascular events. In addition, progression of peripheral
rtery disease now suggests the presence of a more extensive
nd unstable systemic atherosclerotic disease process that
urther magnifies this risk.
There is now overwhelming evidence of the value of the
BI. Despite this evidence, lack of use of this test and
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Can Measuring the ABI Improve Public Health? November 18, 2008:1743–4ssociated under-recognition of PAD have been clearly docu-
ented (13,14), leading to concern that a probable conse-
uence would be inadequate treatment of the associated high
hort-term ischemic risk. Patients with PAD are less inten-
ively treated for their cardiovascular risk factors and are less
ikely to be prescribed antiplatelet therapies than are patients
ith coronary artery disease (2).
Given the wealth of information obtained from this simple
emodynamic test, current cardiovascular guidelines (with
nanimous consensus from the American College of Cardiol-
gy, the American Heart Association, and international vas-
ular specialty societies) have provided the strongest Class 1A
ecommendation for measuring the ABI in “at-risk” popula-
ions (15,16). These recommendations acknowledge the need
o make an accurate diagnosis of PAD in order to provide
roven systemic risk-lowering lifestyle and pharmacologic in-
erventions. In contrast, the U.S. Preventive Services Task
orce recommended against routine screening for PAD (17).
he rationale was that screening with the ABI would not
rovide information “beyond treatment based on standard
ardiovascular risk assessment” and that screening asymptom-
tic adults could lead to increased harm due to “false positive
esults and unnecessary work-ups.” The U.S. Preventive Ser-
ices Task Force did not focus on any of the studies that
emonstrated the utility of the ABI in defining a high-risk, yet
nder-recognized population for cardiovascular events. Clearly
ecent data refute the first assumption, and the second assump-
ion of the U.S. Preventive Services Task Force is unproven.
eyond controversies between conflicting guideline state-
ents, we must avoid a sense of complacency and clinical
nertia that misses opportunities to identify and treat high-risk
opulations, regardless of symptoms.
The challenge we face today is whether measurement of the
BI in appropriate populations would improve public cardio-
ascular health. There are important societal and scientific
uestions that remain as to how primary care physicians would
ncorporate the ABI into assessment of individual patient risk
nd how that information would change their treatment
ecisions. Clinical trials are needed that include measurement
f the ABI as an entry criterion to determine if long-term
reatment strategies targeting PAD improve outcomes. Al-
hough current treatments are effective, novel therapies are still
eeded to reduce cardiovascular risk and manage limb symp-
oms in individuals with PAD. The health care costs of PAD
re extremely high, and outcomes are adverse (18). The ABI is
he only tool at hand that can be deployed now to identify
atients, facilitate treatment, lower costs, and improve out-
omes.
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